Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Research Article

Characteristics and Outcomes of Patients with Anti-Glomerular Basement Membrane Antibody Disease and Anti-Neutrophil Cytoplasmic Antibodies

Author(s): Percy G. Balderia*, Nicole Andeen and Jonathan A. Jefferson

Volume 15, Issue 3, 2019

Page: [224 - 228] Pages: 5

DOI: 10.2174/1573397114666180516131240

Price: $65

Abstract

Background: It is unclear whether patients with Anti-Glomerular Basement Membrane (GBM) disease and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), so called “Double-Positive” (DP), have a different clinical presentation and outcome compared to patients with anti-GBM antibody disease alone. This study describes the clinical and histologic characteristics as well as the patient and renal outcomes of DP patients at the University of Washington compared to patients with anti-GBM antibody disease alone.

Methods: Adults admitted to the University of Washington and Harborview Medical Centers from 2000 to 2016 who had a kidney biopsy showing anti-GBM disease characterized by crescentic glomerulonephritis with strong linear staining of glomerular basement membranes for IgG by immunofluorescence were included. Subjects were classified into anti-GBM or DP based on serologic testing. Information on demographics, clinical presentation, biopsy findings, initial treatment, and rates of relapse and patient and renal survival were collected. Continuous and categorical variables were analyzed using the Mann-Whitney U and Fisher’s exact tests, respectively.

Results: There were 6 anti-GBM and 7 DP patients. Two patients were lost to follow-up after one year. There was no significant difference in clinical presentation or outcomes between the two groups. Two DP patients had greater than 50% global glomerulosclerosis. All the subjects developed ESRD. Two DP patients had a relapse while off immunosuppression. Two patients in each group died within 5 years of diagnosis.

Conclusion: Two DP patients in our cohort had a relapse within 5 years of diagnosis. Multicenter studies are needed to determine whether DP patients have a higher relapse rate and need prolonged immunosuppression.

Keywords: Anti-glomerular basement membrane disease, antineutrophil cytoplasmic antibodies, glomerulonephritis, treatment outcome, immunosuppression, initial treatment.

[1]
Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990; 37(3): 965-70.
[http://dx.doi.org/10.1038/ki.1990.72] [PMID: 2179617]
[2]
Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 1991; 36(3): 107-13.
[PMID: 1657470]
[3]
Bonsib SM, Goeken JA, Kemp JD, Chandran P, Shadur C, Wilson L. Coexistent anti-neutrophil cytoplasmic antibody and antiglomerular basement membrane antibody associated disease = report of six cases. Mod Pathol 1993; 6(5): 526-30.
[PMID: 8248108]
[4]
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies Kidney Int 2004; 66(4): 1535-40.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00917.x] [PMID: 15458448]
[5]
Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46(2): 253-62.
[http://dx.doi.org/10.1053/j.ajkd.2005.05.003] [PMID: 16112043]
[6]
File I, Pucsok K, Trinn C, Ujhelyi L, Balla J, Mátyus J. [Clinical consequence and significance of anti-neutrophil cytoplasmic antibody positivity in anti-glomerular basement membrane disease] Orv Hetil 2013; 154(43): 1696-701.
[http://dx.doi.org/10.1556/OH.2013.29735] [PMID: 24140508]
[7]
Srivastava A, Rao GK, Segal PE, Shah M, Geetha D. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 2013; 32(9): 1317-22.
[http://dx.doi.org/10.1007/s10067-013-2268-5] [PMID: 23624587]
[8]
Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant 2015; 30(5): 814-21.
[http://dx.doi.org/10.1093/ndt/gfu399] [PMID: 25609740]
[9]
McAdoo SP, Tanna A, Hrušková Z, et al. Patients doubleseropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to singleseropositive patients. Kidney Int 2017; 92(3): 693-702.
[http://dx.doi.org/10.1016/j.kint.2017.03.014] [PMID: 28506760]
[10]
Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011; 22(10): 1946-52.
[http://dx.doi.org/10.1681/ASN.2010090928] [PMID: 21868497]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy